Literature DB >> 15142970

Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells.

Nikolaus Marx1, Hélène Duez, Jean-Charles Fruchart, Bart Staels.   

Abstract

A large body of data gathered over the past couple of years has identified the peroxisome proliferator-activated receptors (PPAR) alpha, gamma, and beta/delta as transcription factors exerting modulatory actions in vascular cells. PPARs, which belong to the nuclear receptor family of ligand-activated transcription factors, were originally described as gene regulators of various metabolic pathways. Although the PPARalpha, gamma, and beta/delta subtypes are approximately 60% to 80% homologous in their ligand- and DNA-binding domains, significant differences in ligand and target gene specificities are observed. PPARalpha is activated by polyunsaturated fatty acids and oxidized derivatives and by lipid-modifying drugs of the fibrate family, including fenofibrate or gemfibrozil. PPARalpha controls expression of genes implicated in lipid metabolism. PPARgamma, in contrast, is a key regulator of glucose homeostasis and adipogenesis. Ligands of PPARgamma include naturally occurring FA derivatives, such as hydroxyoctadecadienoic acids (HODEs), prostaglandin derivatives such as 15-deoxyDelta12,14-prostaglandin J2, and glitazones, insulin-sensitizing drugs presently used to treat patients with type 2 diabetes. Ligands for PPARbeta/delta are polyunsaturated fatty acids, prostaglandins, and synthetic compounds, some of which are presently in clinical development. PPARbeta/delta stimulates fatty acid oxidation predominantly acting in muscle. All PPARs are expressed in vascular cells, where they exhibit antiinflammatory and antiatherogenic properties. In addition, studies in various animal models as well as clinical data suggest that PPARalpha and PPARgamma activators can modulate atherogenesis in vivo. At present, no data are available relating to possible effects of PPARbeta/delta agonists on atherogenesis. Given the widespread use of PPARalpha and PPARgamma agonists in patients at high risk for cardiovascular disease, the understanding of their function in the vasculature is not only of basic interest but also has important clinical implications. This review will focus on the role of PPARs in the vasculature and summarize the present understanding of their effects on atherogenesis and its cardiovascular complications.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15142970     DOI: 10.1161/01.RES.0000127122.22685.0A

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  115 in total

1.  Inducing effect of clofibric acid on stearoyl-CoA desaturase in intestinal mucosa of rats.

Authors:  Tohru Yamazaki; Makiko Kadokura; Yuki Mutoh; Takeshi Sakamoto; Mari Okazaki; Atsushi Mitsumoto; Yoichi Kawashima; Naomi Kudo
Journal:  Lipids       Date:  2014-11-02       Impact factor: 1.880

Review 2.  Cardiac metabolic adaptations in response to chronic hypoxia.

Authors:  M Faadiel Essop
Journal:  J Physiol       Date:  2007-08-30       Impact factor: 5.182

3.  Insulin resistance in pulmonary arterial hypertension.

Authors:  R T Zamanian; G Hansmann; S Snook; D Lilienfeld; K M Rappaport; G M Reaven; M Rabinovitch; R L Doyle
Journal:  Eur Respir J       Date:  2008-12-01       Impact factor: 16.671

4.  Regulation of diacylglycerol kinase δ2 expression in C2C12 skeletal muscle cells by free fatty acids.

Authors:  Shizuka Sakiyama; Takako Usuki; Hiromichi Sakai; Fumio Sakane
Journal:  Lipids       Date:  2014-05-23       Impact factor: 1.880

5.  PPARs in atherosclerosis: the clot thickens.

Authors:  Antonio Castrillo; Peter Tontonoz
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

6.  E2/ERβ Inhibits PPARα to Regulate Cell-Proliferation and Enhance Apoptosis in Hep3B-Hepatocellular Carcinoma.

Authors:  Shu Nu Chang-Lee; Hsi-Hsien Hsu; Marthandam Asokan Shibu; Tsung-Jung Ho; Chih-Hao Tsai; Ming-Cheng Chen; Chuan-Chou Tu; Vijaya Padma Viswanadha; Wei- Wen Kuo; Chih-Yang Huang
Journal:  Pathol Oncol Res       Date:  2016-10-18       Impact factor: 3.201

Review 7.  Impact of thiazolidinedione therapy on atherogenesis.

Authors:  Jeroen P H van Wijk; Ton J Rabelink
Journal:  Curr Atheroscler Rep       Date:  2005-09       Impact factor: 5.113

8.  Unbuckling lipodystrophy from insulin resistance and hypertension.

Authors:  Robert A Hegele; Todd Leff
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

9.  An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension.

Authors:  Georg Hansmann; Vinicio A de Jesus Perez; Tero-Pekka Alastalo; Cristina M Alvira; Christophe Guignabert; Janine M Bekker; Stefan Schellong; Takashi Urashima; Lingli Wang; Nicholas W Morrell; Marlene Rabinovitch
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

10.  Fatty acid transduction of nitric oxide signaling: nitrolinoleic acid potently activates endothelial heme oxygenase 1 expression.

Authors:  Marcienne M Wright; Francisco J Schopfer; Paul R S Baker; Vijay Vidyasagar; Pam Powell; Phil Chumley; Karen E Iles; Bruce A Freeman; Anupam Agarwal
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.